Clinical Trial

Nomogram to Predict Breast Cancer Related Lymphedema

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 16, 2020 (before its estimated December 31, 2022 completion). Its status may not reflect the trial's current state.
Summary
It has been hypothesized that damaged arm lymphatic drainage is associated with the arm lymphedema after axillary lymph node dissection (ALND). However, the majority of breast cancer patients with complete ALND has not suffered from arm lymphedema, which appears to be due to the residual arm lymph nodes that has not been removed in the axillary dissection. With the compensation of the residual arm lymph flow above the level of axillary vein, the arm lymphatic drainage could keep balance and remain normal function. This arm lymphedema prediction model that included the protective factor, the proportion of arm lymph flow above the level of axillary vein, allows intraoperative intervention to be performed for the high-risk group. The arm lymphatics of these distinguished patients would be preserved to eliminate the occurrence of arm lymphedema in this study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-12-07.
Trial Details
NCT Number NCT04665882
Lead Sponsor Wuhan University
Conditions Breast Cancer, Axillary Lymph Node Dissection, Breast Cancer Related Lymphedema, Axillary Reverse Mapping
Enrollment 600 participants
Start Date 2020-12-11
Primary Completion 2022-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2020-12-16